Evolucare OphtAI CE certified according to the MDR
The safety and reliability of medical devices are major challenges in the digital transformation of the healthcare sector.
Search results
#Ophthalmology
AIMO-SISO 2025: OphtAI looks forward to seeing you in Italy alongside Topcon Italy!
Du 6 au 8 novembre 2025, l’équipe OphtAI vous attend au congrès AIMO-SISO en Italie, en partenariat avec Topcon, acteur mondial de l’imagerie ophtalmologique.
AI in teleophthalmology: towards optimised eye screening
Teleophthalmology is gradually establishing itself as an effective solution to meet the growing need for screening and monitoring eye diseases...
ESCRS 2025: OphtAI & Adcis look forward to seeing you in Copenhagen!
Click to visit the ESCRS website
From 12 to 16 September, meet our subsidiaries @OphtAI and @Adcis at the Bella Center, booth #E062, on the occasion of the European Society of Cataract and Refractive Surgery congress.
🔬 Adcis will ...
Medical devices: Evolucare obtains MDR certification
INTENSIVE+
A major step forward for digital healthcare: Evolucare is now MDR-certified for all its Medical Devices.
We are proud to announce that our portfolio of medical device products has received MDR (Medical Device Regulation) ...
OphtAI at the SFO 2025 Congress: spotlight on ophthalmological AI
From 10 to 12 May 2025, our subsidiary OphtAI, an artificial intelligence solution dedicated to ophthalmological screening, looks forward to seeing you at the Congress of the French Ophthalmology Society (SFO), stand L15B - level 1, at the ...
International Diabetes Federation (Thaïland)
25th Ophthalmological Reflections Days
Mediterranean Vision Days – 2nd edition
ESCRS Congress – Ophthalmology
The ESCRS congress will be held from September 6 to 10, 2024 in Barcelona.
OphtAI, an Evolucare Group subsidiary specializing in artificial intelligence for ophthalmology, will be presenting the latest developments in its retinal disease ...
SILMO 2024 – Ophthalmology
4rd Retina and Diabetes Day
Aucun résultat ne correspond à votre recherche.